Increasing linkage to hepatitis C care following trauma-informed rehabilitation: An education and quality improvement project among women.

INTRODUCTION The on-going substance use crisis has led to unprecedented rates of hepatitis C virus (HCV) in Canada, with increasing positivity among women who use drugs (WWUD). Despite efforts to reduce barriers to HCV testing and treatment, follow-up remains a major issue. METHODS In this quality improvement project (QIP), we partnered with a short-stay trauma-informed residential drug treatment facility specifically for WWUD, to provide an engaging peer-led HCV education session, followed by low-barrier nurse and peer-led testing and treatment. We sought to evaluate these interventions, as well as determine what factors could improve engagement after women leave. RESULTS The session was attended by 217 participants, 130 completed the survey and 153 opted into testing. Survey results indicated that participants were highly motivated to access general care as well as HCV testing and treatment. The most frequently reported barriers to testing and treatment were a previous negative test and being asymptomatic, respectively. Follow-up facilitators included a non-judgmental provider (88%), monetary incentives (67%), follow-up phone calls (77%), e-mails (66%) and text messages (58%). Of those who were RNA positive, 5 of 13 initiated treatment on-site. By using the results of the QIP in real-time, 6 of 13 were started after leaving the centre (one pending and one lost to follow-up). DISCUSSION AND CONCLUSIONS The implementation of co-localised peer-led testing and treatment for HCV, along with persistent follow-up efforts, led to increases in linkage to care and treatment. Co-localisation of testing and care with substance-use services, especially if residential, is a viable, low-barrier strategy for increasing linkage to care among WWUD.

[1]  B. Mustanski,et al.  Factors associated with self-reported avoidance of harm reduction services during the COVID-19 pandemic by people who use drugs in five cities in the United States and Canada , 2022, Drug and Alcohol Dependence.

[2]  K. Charlton,et al.  Nutrition programmes for individuals living with disadvantage in supported residential settings: a scoping review , 2022, Public Health Nutrition.

[3]  Suzanne D. Turner,et al.  The impact of an integrated safer use space and safer supply program on non-fatal overdose among emergency shelter residents during a COVID-19 outbreak: a case study , 2022, Harm Reduction Journal.

[4]  Davinia B. Rizzo,et al.  Barriers to Accessing Addiction Treatment for Women at Risk of Homelessness , 2022, Frontiers in Global Women's Health.

[5]  J. Feld,et al.  Remaining challenges in HCV elimination , 2021, Journal of Hepatology.

[6]  J. Lazarus,et al.  Reducing Read Time of Point of Care Test Does Not Affect Detection of Hepatitis C Virus and Reduces Need for Reflex RNA. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  Elina Virokannas.  Treatment Barriers to Social and Health Care Services from the Standpoint of Female Substance Users in Finland , 2020, Journal of Social Service Research.

[8]  A. Duberg,et al.  Frequent loss to follow‐up after diagnosis of hepatitis C virus infection: A barrier towards the elimination of hepatitis C virus , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[9]  S. Goldenberg,et al.  Police-related barriers to harm reduction linked to non-fatal overdose amongst sex workers who use drugs: Results of a community-based cohort in Metro Vancouver, Canada. , 2019, The International journal on drug policy.

[10]  T. Baggett,et al.  Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston. , 2019, The International journal on drug policy.

[11]  M. Manns,et al.  Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications , 2019, Visceral Medicine.

[12]  M. Mimiaga,et al.  Strategies used by people who inject drugs to avoid stigma in healthcare settings. , 2019, Drug and alcohol dependence.

[13]  D. Pourmarzi,et al.  Clinical effectiveness, cost effectiveness and acceptability of community‐based treatment of hepatitis C virus infection: A mixed method systematic review , 2019, Journal of viral hepatitis.

[14]  A. K. Burlew,,et al.  Research on women with substance use disorders: Reviewing progress and developing a research and implementation roadmap. , 2019, Drug and alcohol dependence.

[15]  N. Janjua,et al.  Contextualizing Canada's hepatitis C virus epidemic. , 2018, Canadian liver journal.

[16]  C. Treloar,et al.  Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs? , 2018, PloS one.

[17]  E. Wood,et al.  Hepatitis C Cascade of Care among People who Inject Drugs in Vancouver, Canada , 2018, Substance abuse.

[18]  M. Skeer,et al.  'Hep C's like the common cold': understanding barriers along the HCV care continuum among young people who inject drugs. , 2018, Drug and alcohol dependence.

[19]  J. Powis,et al.  From client to co-worker: a case study of the transition to peer work within a multi-disciplinary hepatitis c treatment team in Toronto, Canada , 2018, Harm Reduction Journal.

[20]  Mary E. Larimer,et al.  Using text message reminders in health care services: A narrative literature review , 2018, Internet interventions.

[21]  M. Conaway,et al.  PositiveLinks: A Mobile Health Intervention for Retention in HIV Care and Clinical Outcomes with 12-Month Follow-Up , 2018, AIDS patient care and STDs.

[22]  A. Story,et al.  What works in inclusion health: overview of effective interventions for marginalised and excluded populations , 2017, The Lancet.

[23]  R. Heimer,et al.  Barriers and facilitators of the HIV care continuum in Southern New England for people with drug or alcohol use and living with HIV/AIDS: perspectives of HIV surveillance experts and service providers , 2017, Addiction Science & Clinical Practice.

[24]  S. Antinori,et al.  Direct‐acting antivirals in hepatitis C virus (HCV)‐infected and HCV/HIV‐coinfected patients: real‐life safety and efficacy , 2017, HIV medicine.

[25]  Jennifer I. Manuel,et al.  Barriers and facilitators to successful transition from long-term residential substance abuse treatment. , 2017, Journal of substance abuse treatment.

[26]  J. Kelly,et al.  Barriers and Facilitators of HIV Care Engagement: Results of a Qualitative Study in St. Petersburg, Russia , 2016, AIDS and Behavior.

[27]  C. Feng,et al.  Gender influences on hepatitis C incidence among street youth in a Canadian setting. , 2014, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[28]  G. Dusheiko,et al.  Natural history of hepatitis C. , 2014, Journal of hepatology.

[29]  E. Coleman,et al.  Enhancing Transitions from Addiction Treatment to Primary Care , 2014, Journal of addictive diseases.

[30]  J. Powis,et al.  Factors associated with HCV antiviral treatment uptake among participants of a community‐based HCV programme for marginalized patients , 2012, Journal of viral hepatitis.

[31]  K. Merikangas,et al.  Epidemiology of substance use disorders , 2012, Human Genetics.

[32]  Linda C Gallo,et al.  Peer-Led Diabetes Education Programs in High-Risk Mexican Americans Improve Glycemic Control Compared With Standard Approaches , 2011, Diabetes Care.

[33]  R. Ruiter,et al.  The Effectiveness of a Peer-Led HIV/AIDS and STI Health Education Intervention for Prison Inmates in South Africa , 2008, Health education & behavior : the official publication of the Society for Public Health Education.

[34]  T. Conklin,et al.  Facilitators and Barriers to Continuing Healthcare After Jail: A Community‐integrated Program , 2006, The Journal of ambulatory care management.

[35]  Mary Jo Larson,et al.  Linkage with primary medical care in a prospective cohort of adults with addictions in inpatient detoxification: room for improvement. , 2004, Health services research.

[36]  J. Berek,et al.  Reducing loss-to-follow-up among women with abnormal Pap smears. Results from a randomized trial testing an intensive follow-up protocol and economic incentives. , 1998, Medical care.

[37]  B. Grant,et al.  Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. , 2007, Archives of general psychiatry.